NASDAQ:VIR Vir Biotechnology - VIR News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $30.85 +0.86 (+2.87%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$29.91▼$31.5550-Day Range$24.80▼$30.8552-Week Range$18.05▼$35.48Volume767,934 shsAverage Volume697,478 shsMarket Capitalization$4.11 billionP/E Ratio3.63Dividend YieldN/APrice Target$52.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Media Mentions By Week VIR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼0.410.71▲Average Medical News Sentiment VIR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼254▲VIR Articles Average Week All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineRoyce & Associates LP Invests $546,000 in Vir Biotechnology, Inc. (NASDAQ:VIR)marketbeat.com - January 27 at 5:35 AMBank Julius Baer & Co. Ltd Zurich Sells 65,007 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)marketbeat.com - January 26 at 7:14 AMComerica Bank Sells 5,405 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)marketbeat.com - January 24 at 4:29 AMLos Angeles Capital Management LLC Boosts Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)marketbeat.com - January 23 at 5:52 AMVir Biotechnology (NASDAQ:VIR) Upgraded to "Equal Weight" at Morgan Stanleyamericanbankingnews.com - January 28 at 6:28 AMVir Biotechnology (NASDAQ:VIR) Price Target Cut to $43.00 by Analysts at SVB Leerinkamericanbankingnews.com - January 28 at 6:28 AMEndurance (Cayman) Ltd Svf Sells 36,512 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stockamericanbankingnews.com - January 28 at 5:10 AMInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Insider Sells 30,000 Shares of Stockamericanbankingnews.com - January 28 at 5:10 AMSVB Securities Keeps Their Buy Rating on Vir Biotechnology (VIR)markets.businessinsider.com - January 27 at 8:16 AMAnalyst Expectations for Vir Biotechnology's Futuremarkets.businessinsider.com - January 27 at 8:16 AM'You have to have the goods': Retiring Vir CEO George Scangos looks back on building great companiesbizjournals.com - January 26 at 9:20 AM'You have to have the goods': Retiring Vir CEO George Scangos on building great companiesfinance.yahoo.com - January 25 at 6:52 PMWednesday Digest: S.F. sets a massive housing goal; Biotech names a new CEObizjournals.com - January 25 at 1:23 PMCovid Drugmaker Vir Replaces CEO With Bayer Executive as It Searches for Next Hitbloomberg.com - January 25 at 1:23 PMVir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successorfinance.yahoo.com - January 25 at 8:51 AMEndurance (Cayman) Ltd Svf Sells 69,839 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stockamericanbankingnews.com - January 25 at 4:32 AMVir Biotechnology, Inc. (VIR) Moves to Strong Buy: Rationale Behind the Upgradefinance.yahoo.com - January 24 at 2:39 PM2 Stocks That Could Turn $100 Into $1,000 by 2028msn.com - January 22 at 8:07 AM10 Best Healthcare Stocks For the Long Termfinance.yahoo.com - January 21 at 6:11 PMAre Robust Financials Driving The Recent Rally In Vir Biotechnology, Inc.'s (NASDAQ:VIR) Stock?finance.yahoo.com - January 21 at 8:10 AMIs Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?finance.yahoo.com - January 20 at 1:48 PMVir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 88,372 Shares of Stockamericanbankingnews.com - January 20 at 6:16 AMVir Biotechnology: High Potential Returns With High Volatility Risksseekingalpha.com - January 19 at 7:47 AMVir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 94,199 Sharesamericanbankingnews.com - January 19 at 4:12 AMFormer CEO says Biogen 'shot themselves in the foot' by deciding to charge $56,000 for its controversial Alzheimer's drugbusinessinsider.com - January 18 at 8:37 AMAnalysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $52.50americanbankingnews.com - January 18 at 4:02 AMVir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 4:59 PMAre Investors Undervaluing Vir Biotechnology, Inc. (NASDAQ:VIR) By 32%?finance.yahoo.com - December 31 at 12:13 PMDrug companies set sights on new COVID medicines to boost depleted arsenalmsn.com - December 27 at 8:26 PMDrug companies set sights on new COVID medicines to boost depleted arsenalmsn.com - December 27 at 8:26 PMVir Biotechnology: A 'Magic Formula' Top Performerfinance.yahoo.com - December 22 at 6:12 PMVir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza Afinance.yahoo.com - December 21 at 9:18 AMVir Biotechnology: Collaborative Approach To Taking On Serious Diseasesseekingalpha.com - December 17 at 10:22 AMWith 49% stake, Vir Biotechnology, Inc. (NASDAQ:VIR) seems to have captured institutional investors' interestfinance.yahoo.com - December 6 at 8:54 AM2 Fast-Growing Healthcare Stocks to Buy and Holdfinance.yahoo.com - December 2 at 9:12 AMBioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analystsmarkets.businessinsider.com - December 2 at 7:08 AMWall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 71%: Here's is How to Tradefinance.yahoo.com - November 24 at 2:13 PMShould Value Investors Buy Vir Biotechnology (VIR) Stock?finance.yahoo.com - November 22 at 4:30 PMAfter Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trademsn.com - November 18 at 4:44 PM99 Bay Area companies named in Deloitte 'fast 500' list, including its No. 1bizjournals.com - November 18 at 9:11 AM99 Bay Area companies named in Deloitte's Technology Fast 500 list, including its No. 1finance.yahoo.com - November 18 at 9:11 AMVir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™finance.yahoo.com - November 16 at 4:06 PMVir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™finance.yahoo.com - November 16 at 4:06 PMMoore Kuehn, PLLC Encourages Investors of Vir Biotechnology, Inc. to Contact Law Firmbenzinga.com - November 10 at 5:23 PMVir Biotechnology Third Quarter 2022 Earnings: Beats Expectationsfinance.yahoo.com - November 9 at 10:33 AMWall Street Analysts Predict a 107% Upside in Vir Biotechnology, Inc. (VIR): Here's What You Should Knowfinance.yahoo.com - November 8 at 2:59 PMWhy MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Fridaymsn.com - November 7 at 4:46 AMVir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infectionfinance.yahoo.com - November 6 at 5:18 PMAnalyst Forecasts For Vir Biotechnology, Inc. (NASDAQ:VIR) Are Surging Higherfinance.yahoo.com - November 5 at 1:41 PMTop Biotech Stocks for Q4 2022finance.yahoo.com - November 4 at 7:04 PMWhy Vir Biotechnology Jumped Nearly 19% Todayfinance.yahoo.com - November 4 at 4:48 PMNeedham Reaffirms Their Buy Rating on Vir Biotechnology (VIR)markets.businessinsider.com - November 4 at 2:02 PMWhat 5 Analyst Ratings Have To Say About Vir Biotechnologymarkets.businessinsider.com - November 4 at 2:02 PMVir Biotechnology, Inc. (VIR) Q3 Earnings and Revenues Surpass Estimatesfinance.yahoo.com - November 4 at 2:02 PM Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:VIR) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.